Table 3: Micro-CT analysis of bone at drill-hole site
Parameters
Acknowledgement
Authors are thankful to CSIR and UGC for providing
Control
1 mg/kg
fellowships. Saransh W. Maurya is thankful to University of
Allahabad, Allahabad for providing fellowship and Director
CSIR-CDRI for providing opportunity of academic training in
CDRI, Lucknow, India. Rakesh Maurya is grateful to CSIR, New
Delhi, India, for providing emeritus scientist scheme with
reference no. 21(1019)/16/EMR-II. The grant from DBT
(Department of Biotechnology GAP0127), CSIR sponsored
network project CSC0130, BSC103, AcSIR and CSIR,
Government of India are acknowledgment. Authors are also
grateful to SAIF division of CDRI for providing spectral data.
BV/TV (%)
Tb.Th (mm)
Tb.No (mm-1)
Tb.Sp (mm)
SMI
32.924 3.806
0.111 0.006
2.194 0.265
0.219 0.015
2.585 0.387
44.359 1.912*
0.166 0.010***
3.442 0.262**
0.164 0.007**
0.496 0.081***
Compound 4d (1mg/kg) improves micro-architectural parameters at the
drill-hole site. Bone volume/tissue volume (BV/TV), Trabecular thickness.
(Tb.Th), Trabecular number (Tb.No), Trabecular separation (Tb.Sp),
Structure model index (SMI). All values are expressed as mean
SE;
*P< 0.05; **P< 0.01 and ***P< 0.001.
References
1. Allen, J. G.; Fotsch, C.; Babij, P. J. Med. Chem. 2010, 53,
4332.
We further investigated osteogenic and chondrogenic
genes expression during fracture healing in bone including Sox9,
aggrecan, RunX2, BMP2, BMP4, OCN and COL1. As shown in
Fig. 7(B), the results revealed that daily administration of
compound 4d of 1.0 mg dose exhibited increase in the mRNA
levels of Sox9 (p<0.05), aggrecan (p<0.05) and BMP4 (p<0.05).
RunX2 and BMP2 have increased but not significant. At 1.0
mg/kg dose of 4d had a robust induction of ~6 folds on the
mRNA levels of OCN and mineralizing gene COL1(p<0.05) over
the control.
2. (a). Oursler, M. J.; Landers, J. P.; Riggs, B. L.; Spelsberg,
T. C. Ann. Med. 1993, 25, 361. (b). Paul, J. C.; Karen, M.
B.; Ben, C. A.; John, H. H.; Carol, A. M.; Le, T. D.;
Bradley, P. F.; Carmen, F. M.; Michael, A. G.; George, D.
H.; Donald, B. K.; Chih-Tai, L.; Lorraine, L.; Kara, M.;
Brenda, P.; Thomayant, P.; Gideon, A.; Rodan, G. A.;
Wesolowski, S. B.; Rodan, M. E. D. J. Med. Chem. 2004,
47, 4829.
3. Riggs, B. L.; Wahner, H. W.; Dunn, W. L.; Mazess, R. B.;
Offord, K. P.; Melton, L. J. III. J. Clin. Invest. 1981, 67,
328.
4. Ettinger, B.; Pressman, A.; Silver, P. Menopause 1999, 6,
282.
5. Liu, Z. Y.; He, X. B.; Yang, Z. Y.; Shao, H.Y.; Li, X.;
Guo. H. F.; Zhang, Y. Q.; Si, S. Y.; Li, Z. R. Bioorg. Med.
Chem. Lett. 2009, 19, 4167.
6. Han, C. Y. E.; Wang, Y.; Yu, L.; Powers, D.; Xiong, X.;
Yu, V.; Nguyen, Y.; Jean, D. J. S. Jr.; Babij, P.; Bioorg.
Med. Chem. Lett. 2009, 19, 1442.
7. Donnelly, D. M. X.; Boland, G. M. Nat. Prod. Rep. 1995,
12, 321.
8. de Lima, O. G., Maia, M. H. D., d'Albuquerque, I. L., de
Albuquerque, M. M. F., Borba, M. A. P. Rev. Inst.
Antibiot. Univ. Recife 1961, 3, 61.
9. Shirota, O., Pathak, V., Sekita, S., Satake, M., Nagashima,
Y., Hirayama, Y., Hakamata, Y., Hayashi, T. J. Nat. Prod.
2003, 66, 1128.
10. (a) Kumar, P.; Kushwaha, P.; Khedgikar, V.; Gautam, J.;
Choudhary, D.; Singh, D.; Trivedi, R.; Maurya, R. Bioorg.
Med. Chem. Lett. 2014, 24, 2664. (b) Choudhary, D.,
Kushwaha, P., Gautam, J., Kumar, P., Verma, A., Kumar,
A., Maurya, S. W., Siddiqui, I. R., Mishra, P. R., Maurya,
R., Trivedi, R. Biomed. Pharmacother. 2016, 83, 942.
11. Sekine, N., Ashitani, T., Murayama, T., Ogiyama,
K.,Takahashi, K. Mokuzai Gakkaishi 2009, 55, 29.
12. Wu, S. F., Chang, F. R., Wang, S. Y., Hwang, T. L., Lee,
C. L., Chen, S. L., Wu, C. C., Wu, Y. C. J. Nat. Prod.
2011, 74, 989.
13. Zhaoa, C., Liub, Y., Conga, D., Zhangc, H., Yua, J.,
Jianga, Y., Cuia, X., Sunc, J. Biomed. Chromatogr. 2013,
27, 1621.
14. Esterbauer, H., Poelsler, G., Fodor, G. Acta Biochim.
Biophys. 1987, 22, 195.
Fig. 7 Compound 4d enhances bone healing at the drill-hole site in the
treatment group. (A) Representative µCT 2-D images from different groups
showing callus formation at the drill-hole site in femoral bone of mice. (B)
Relative m-RNA expression of Sox9, Aggrecan, RunX2, BMP2, BMP4,
OCN and COL1 in callus at the drill-hole site and compared with control
group. All data were represented as the mean SE. ∗∗p<0.01and ∗p<0.05
with three independent experiments.
The structure-activity relationship revealed that the
compounds having extended aliphatic linker chain the osteogenic
activity was significantly increased. The introduction of aliphatic
chain from one carbon to five carbon at position 6 of dalbergin
enhances the ALP activity. To evaluate the effect of bromo group
on ALP mineralization, we replaced it by cyclic amines and a
significant increase in ALP activity was observed. Further, the
introduction of ester groups instead of the aliphatic chain was
found to enable in the enhancement of ALP activity. Similarly,
the synthesized amide compound was also found to inactive.
In conclusion, we have synthesized twenty three novel
analogues of naturally occurring dalbergin in concise, efficient
and economical synthetic routes. Syntheses of these new
analogues aim to explore the chemical modification of dalbergin
and to investigate their role in the treatment of osteoporosis.
Among all twenty three derivatives, four compounds 2d, 3a, 4a,
and 4d showed significant ALP activity and mineralization in
calvarial cells. The compound 4d was found to be most potent
and showed a significant osteoprotective effect at 1.0 mg/kg/d in
in vivo assay.
15. Mutai, P.; Heydenreich, M.; Thoithi, G.; Mugumbate, G.;
Chibale, K.; Yenesew, A. Phytochem. Lett. 2013, 6, 671.
16. Chunfang, Z.; Yongqiang L.; Cong, D.; Hui Z.; Yu, Jiang
J.; Cui Y.; Sun, X. J. Biomed. Chromatogr. 2013, 27, 1621.
17. Cheng, Y.; Wang, Y.; Ge, Z.; Li, Y. Faming Zhuanli
Shenqing 2011, CN 102133260 A 20110727.
18. Kawase, M.; Sakagami, H.; Motohashi, N.; Hauer, H.;
Chatterjee, S. S.; Spengler, G.; Vigyikanne, A. V.; Molnar,
A.; Molnar, J. In Vivo 2005, 19, 705.